PRESS RELEASE
ERYTECH announces that Akkadian continues its attempt at destabilization with the introduction of a new legal action
Lyon (France), June 20, 2023 – ERYTECH Pharma (Euronext Paris and Nasdaq: ERYP) announces the filing of a new legal action by Akkadian Partners.
Despite the rejection by the President of the Commercial Court of Lyon of Akkadian Partners’ request to postpone the vote of the general meeting on the proposed merger, Akkadian has initiated new legal proceedings with the clear aim of pursuing its attempt to destabilize Erytech.
As part of this new procedure, the first hearing of which will take place after the vote on the merger, Akkadian Partners is requesting the cancellation of the capital increase of May 15, 2023. This capital increase, resulting from contributions in kind from shares of Pherecydes in return for shares of ERYTECH, had been announced when the merger was announced last February and had been carried out by virtue of the delegation of authority granted by the Extraordinary General Meeting of ERYTECH shareholders of June 24, 2022 (29
th
resolution) and on the basis of the reports submitted by Finexsi, acting as contribution auditor, in accordance with Articles L. 225-147, R. 22-10-7 and R. 225-136 of the French Commercial Code as well as the AMF position-recommendation no. 2020-06.
Erytech is confident about the outcome of this unfounded procedure which appears doomed to failure.
About ERYTECH:
www.erytech.com
ERYTECH is a biopharmaceutical company that develops innovative treatments based on red blood cells to fight against cancers and orphan diseases.
On February 15, 2023, ERYTECH announced its planned strategic merger with PHERECYDES to create a global player in phage therapy. More details are available in the press release.
ERYTECH is listed on the Nasdaq Capital Market in the United States (symbol: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135; symbol: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indices.
For more information, please visit www.erytech.com
CONTACTS
|
ERYTECH Eric Soyer Chief Financial Officer and Director of Operations |
NewCap Mathilde Bohin/Louis-Victor Delouvrier Investor Relations Nicolas Merigeau Media Relations |
+33 (0)4 78 74 44 38 | +33 (0)1 44 71 94 94 |
Attachment